Valvular heart disease management guidelines were updated last week by the AHA and the ACC.  The last complete version had been published in 2014; therefore many of its recommendations have become obsolete before the latest evidence.  The studies that made the FDA approve TAVI for low-risk patients are probably the most important incorporations. They also…